Speaker illustration

Doctor Mikhail Kosiborod

St. Luke's Mid America Heart Institute, Kansas City (United States of America)

The obesity phenotype of HFpEF: new therapies on our door step?

Event: ESC Congress 2023

Topic: Chronic Heart Failure

Session type: Satellite Symposium

Thumbnail

Finerenone: a disease-modifying therapy for heart and kidney protection

Event: ESC Congress 2023

Topic: Clinical

Session type: Satellite Symposium

Thumbnail

Tackling the risk of hyperkalaemia through guideline-recommended heart failure therapy

Event: ESC Congress 2023

Topic: Chronic Heart Failure

Session type: Satellite Symposium

Thumbnail

HFpEF: a great unmet need?

Event: Heart Failure 2023

Topic: Chronic Heart Failure

Session type: Satellite Symposium

Thumbnail

Breaking barriers in guideline-based RAASi-therapy: solving issues with hyperkalemia

Event: Heart Failure 2023

Topic: Treatment

Session type: Satellite Symposium

Thumbnail

What's the next STEP in HFpEF?

Event: Heart Failure 2022

Topic: Chronic Heart Failure

Session type: Satellite Symposium

Thumbnail

Glucagon-like peptide 1 receptor agonists in clinical cardiology practice

Event: ESC Congress 2021 - The Digital Experience

Topic: Risk Factors and Prevention

Session type: Satellite Symposium

Thumbnail

Consequences of COVID-19 in heart failure: one year on

Event: ESC Congress 2021 - The Digital Experience

Topic: Chronic Heart Failure

Session type: Abstract Sessions

Thumbnail

6 years on, what have we learned from Real World use of PCSK9i?

Event: ESC Congress 2021 - The Digital Experience

Topic: Lipids

Session type: Satellite Symposium

Thumbnail

Experts on the spot: exploring new dimensions in glucagon-like peptide-1 receptor agonists and cardiovascular risk

Event: ESC Congress 2019

Topic: Cardiovascular Disease in Special Populations

Session type: Satellite Symposium - Experts on the Spot

Thumbnail